Communicating Health Options to Inform Care and Empower Strategic Care Planning (CHOICES): A Multi-layer Randomized Case Vignette Study.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06722846

Enrollment

400

Registered

2024-12-09

Start date

2024-11-21

Completion date

2028-08-31

Last updated

2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Options, Strategic Care Planning

Brief summary

To learn more about how the delivery of medical information affects therapy choices for participants with advanced forms of cancer.

Detailed description

Primary Objectives • To examine how provision of medical information (risks, benefits, time toxicity, prognosis, oncologists' recommendation, and costs) affects preference for palliative systemic therapy in participants with advanced cancer. Secondary Objective • To examine how different options of medical information (risks/benefits, time toxicity, prognosis, oncologists' recommendation, and costs) affect preference for palliative systemic therapy in participants with advanced cancer. Exploratory Objective * To examine how the order of presentation of medical information affects preference for palliative systemic therapy in participants with advanced cancer. * To examine the association between intrinsic participants characteristics (such as participants demographics, symptoms, anxiety, depression, illness understanding, acceptance, coping strategies, religious coping, hope, decision making style, trust in oncologist, financial distress) and preference for palliative systemic therapy in participants with advanced cancer.

Interventions

BEHAVIORALRandomized Case Vignette Study

Particpants will complete about 16 questionnaires that will have questions about particpants quality of life, anxiety, health, andcase scenarios that are not real or based on particpants actual health situation.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

Diagnosis of advanced solid tumor (i.e. metastatic, relapsed, and/or incurable disease) or aggressive lymphoma. * Age 18 or greater * Seen at MD Anderson Cancer Center Thoracic and Lymphoma Oncology Clinics for a follow-up visit * Been treated with at least 2 lines of palliative systemic cancer therapies

Exclusion criteria

* Diagnosis of cognitive impairment or dementia requiring a surrogate decision maker * Non-English speaking

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival (OS)	Through study completion; an average of 1 year.	Progression Free Survival (PFS)

Countries

United States

Contacts

CONTACTDavid Hui, MD

dhui@mdanderson.org713-792-6258

PRINCIPAL_INVESTIGATORDavid Hui, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026